These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32112204)

  • 21. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.
    Hall GC; McMahon AD; Dain MP; Wang E; Home PD
    Diabet Med; 2013 Jun; 30(6):681-6. PubMed ID: 23330649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
    Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
    Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2019 Nov; 21(11):2542-2552. PubMed ID: 31364233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.
    Boye KS; Mody R; Lage MJ; Malik RE
    Clin Ther; 2020 Sep; 42(9):1812-1817.e2. PubMed ID: 32741645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.
    Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C
    Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.
    Tramunt B; Disse E; Chevalier N; Bordier L; Cazals L; Dupuy O; Marre M; Matar O; Meyer L; Noilhan C; Sanz C; Valensi P; Velayoudom FL; Gautier JF; Gourdy P
    Diabetes Ther; 2022 Dec; 13(11-12):1947-1963. PubMed ID: 36331712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
    Hoog M; Smith JL; Yu M; Peleshok J; Mody R; Grabner M
    Clin Ther; 2022 Jun; 44(6):873-887. PubMed ID: 35618571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.
    Hopton OM; Waterbury NV; Egge JA; Lund BC
    Pharmacotherapy; 2022 Jan; 42(1):45-52. PubMed ID: 34807465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
    Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
    Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
    Digenio A; Karve S; Candrilli SD; Dalal M
    Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.